{"id":"NCT01458574","sponsor":"Pfizer","briefTitle":"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis","officialTitle":"A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07-20","primaryCompletion":"2016-05-27","completion":"2016-05-27","firstPosted":"2011-10-25","resultsPosted":"2017-05-18","lastUpdate":"2017-05-18"},"enrollment":593,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"CP690,550","otherNames":[]},{"type":"DRUG","name":"CP-690,550","otherNames":[]}],"arms":[{"label":"Placebo Comparator","type":"PLACEBO_COMPARATOR"},{"label":"CP-690,550 5 mg Arm","type":"EXPERIMENTAL"},{"label":"CP-690,550 10 mg Arm","type":"EXPERIMENTAL"}],"summary":"The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC). The study proposes to assess whether compared to placebo, CP-690,550 maintenance therapy more effectively achieves mucosal healing and improves quality of life in subjects with UC.The study proposes to assess CP-690,550 pharmacokinetic exposure during maintenance therapy in subjects over the age of 18 years with UC.","primaryOutcome":{"measure":"Percentage of Participants In Remission at Week 52","timeFrame":"Week 52","effectByArm":[{"arm":"Tofacitinib 5 mg BID","deltaMin":34.3,"sd":null},{"arm":"Tofacitinib 10 mg BID","deltaMin":40.6,"sd":null},{"arm":"Placebo","deltaMin":11.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":275,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Colombia","Croatia","Czechia","Denmark","Estonia","France","Germany","Hungary","Israel","Italy","Japan","Latvia","Netherlands","New Zealand","Poland","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["38778549","38425446","37560161","37402275","36931693","36755231","36526796","36506749","36342120","36336750","36271912","36124702","35792493","35648151","35574426","35380740","34614208","34165201","34035832","33884415","33684552","33513294","33324993","33039585","32870265","32816215","32766762","31599001","31077827","30476584","29850873","29743836","29028981","28467869"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921096&StudyName=A%20Study%20Of%20Oral%20CP-690%2C550%20As%20A%20Maintenance%20Therapy%20For%20Ulcerative%20Colitis"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":198},"commonTop":["Colitis ulcerative","Nasopharyngitis","Arthralgia","Headache","Upper respiratory tract infection"]}}